This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Previously Presented) A compound of formula



(I),

a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein

ring A is phenyl;

$R^1$ represents hydrogen; aryl; formyl; $C_{1-6}$alkylcarbonyl; $C_{1-6}$alkyl; $C_{1-6}$alkyloxycarbonyl; $C_{1-6}$alkyl substituted with formyl, $C_{1-6}$alkylcarbonyl, $C_{1-6}$alkyloxycarbonyl, $C_{1-6}$alkylcarbonyloxy; or $C_{1-6}$alkyloxy$C_{1-6}$alkylcarbonyl optionally substituted with $C_{1-6}$alkyloxycarbonyl;

$X_1$ represents a direct bond; $-(CH_2)_{n3}-$ or $-(CH_2)_{n4}-X_{1a}-X_{1b}-$;

with $n_3$ representing an integer with value 1, 2, 3 or 4;

with $n_4$ representing an integer with value 1 or 2;

with $X_{1a}$ representing O, C(=O) or $NR^5$; and

with $X_{1b}$ representing a direct bond or $C_{1-2}$alkyl;

$R^2$ represents $C_{3-7}$cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula



(a-1)

wherein –B-C- represents a bivalent radical of formula

$-CH_2-CH_2-CH_2-$ (b-1);

$-CH_2-CH_2-CH_2-CH_2-$ (b-2);

$-X_3-CH_2-CH_2-(CH_2)_n-$ (b-3);

$-X_3-CH_2-(CH_2)_n-X_3-$ (b-4);

$-X_3-(CH_2)_{n'}-CH=CH-$ (b-5);

$-CH=N-X_3-$ (b-6);

with $X_3$ representing O or $NR^5$;

n representing an integer with value 0, 1, 2 or 3;

n' representing an integer with value 0 or 1;

wherein said $R^2$ substituent, where possible, may optionally be substituted with at least one substituent selected from halo; hydroxy; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo-$C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{1-6}$alkyloxy optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo$C_{1-6}$alkyloxy optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{1-6}$alkylthio; polyhalo$C_{1-6}$alkylthio; $C_{1-6}$alkyloxycarbonyl; $C_{1-6}$alkylcarbonyloxy; $C_{1-6}$alkylcarbonyl; polyhalo$C_{1-6}$alkylcarbonyl; cyano; carboxyl; aryloxy; arylthio; arylcarbonyl; aryl$C_{1-4}$alkyl; aryl$C_{1-4}$alkyloxy; $NR^6R^7$; $C(=O)NR^6R^7$; $-NR^5-C(=O)-NR^6R^7$; $-NR^5-C(=O)-R^5$; $-S(=O)_{n1}-R^8$; $-NR^5-S(=O)_{n1}-R^8$; -S-CN; $-NR^5$-CN; oxazolyl optionally substituted with $C_{1-4}$alkyl; imidazolyl optionally substituted with $C_{1-4}$alkyl; or



with n2 representing an integer with value 0, 1, 2, 3 or 4;
with $X_4$ representing O, $NR^5$ or a direct bond;
with $X_5$ representing O, $CH_2$, CHOH, $CH-N(R_5)_2$, $NR^5$ or $N-C(=O)-C_{1-4}$alkyl;

$X_2$ represents a direct bond; $-NR^1-$; $-NR^1-(CH_2)_{n3}-$; -O-; $-O-(CH_2)_{n3}-$; -C(=O)-; $-C(=O)-(CH_2)_{n3}-$; $-C(=O)-NR^5-(CH_2)_{n3}-$; -C(=S)-; -S-; $-S(=O)_{n1}-$; $-(CH_2)_{n3}-$;

$-(CH_2)_{n4}-X_{1a}-X_{1b}-$; $-X_{1a}-X_{1b}-(CH_2)_{n4}-$; $-S(=O)_{n1}-NR^5-(CH_2)_{n3}-NR^5-$; or $-S(=O)_{n1}-NR^5-(CH_2)_{n3}-$;

$R^3$ represents a 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from O, S or N, wherein said $R^3$ substituent, where possible, may optionally be substituted with at least one substituent selected from halo; hydroxy; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo$C_{1-6}$alkyl; $C_{1-6}$alkyloxy optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo$C_{1-6}$alkyloxy; $C_{1-6}$alkylthio; polyhalo$C_{1-6}$alkylthio; $C_{1-6}$alkyloxycarbonyl; $C_{1-6}$alkylcarbonyloxy; $C_{1-6}$alkylcarbonyl; polyhalo$C_{1-6}$alkylcarbonyl; cyano; carboxyl; $NR^6R^7$; $C(=O)NR^6R^7$; $-NR^5-C(=O)-NR^6R^7$; $-NR^5-C(=O)-R^5$; $-S(=O)_{n1}-R^8$; $-NR^5-S(=O)_{n1}-R^8$; -S-CN; $-NR^5-CN$; or  ; and in case $R^3$ represents a saturated or a partially saturated 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, said $R^3$ may also be substituted with at least one oxo;

$R^4$ represents hydrogen; halo; hydroxy; $C_{1-4}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^9R^{10}$, $-C(=O)-NR^9R^{10}$, $-NR^5-C(=O)-NR^9R^{10}$, $-S(=O)_{n1}-R^{11}$ or $-NR^5-S(=O)_{n1}-R^{11}$; $C_{2-4}$alkenyl or $C_{2-4}$alkynyl, each optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^9R^{10}$, $-C(=O)-NR^9R^{10}$, $-NR^5-C(=O)-NR^9R^{10}$, $-S(=O)_{n1}-R^{11}$ or $-NR^5-S(=O)_{n1}-R^{11}$; polyhalo$C_{1-3}$alkyl; $C_{1-4}$alkyloxy optionally substituted with carboxyl; polyhalo$C_{1-3}$alkyloxy; $C_{1-4}$alkylthio; polyhalo$C_{1-3}$alkylthio;

$C_{1-4}$alkyloxycarbonyl; $C_{1-4}$alkylcarbonyloxy; $C_{1-4}$alkylcarbonyl; polyhalo$C_{1-4}$alkylcarbonyl; nitro; cyano; carboxyl; $NR^9R^{10}$; $C(=O)NR^9R^{10}$; $-NR^5-C(=O)-NR^9R^{10}$; $-NR^5-C(=O)-R^5$; $-S(=O)_{n1}-R^{11}$; $-NR^5-S(=O)_{n1}-R^{11}$; -S-CN; or $-NR^5-CN$;

$R^5$ represents hydrogen, $C_{1-4}$alkyl or $C_{2-4}$alkenyl;

$R^6$ and $R^7$ each independently represent hydrogen; cyano; $C_{1-6}$alkylcarbonyl optionally substituted with $C_{1-4}$alkyloxy or carboxyl; $C_{1-6}$alkyloxycarbonyl; $C_{3-7}$cycloalkylcarbonyl; adamantanylcarbonyl; $C_{1-4}$alkyloxy$C_{1-4}$alkyl; $C_{1-4}$alkyl substituted with $C_{1-4}$alkyl-$NR^5$-; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from halo, hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, polyhalo$C_{1-4}$alkyl, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $NR^{6a}R^{7a}$, $C(=O)NR^{6a}R^{7a}$ or  ; with $X_6$ representing O, $CH_2$, CHOH, $CH-N(R_5)_2$, $NR^5$ or N-C(=O)-$C_{1-4}$alkyl;

$R^{6a}$ and $R^{7a}$ each independently represent hydrogen; $C_{1-4}$alkyl or $C_{1-4}$alkylcarbonyl;

$R^8$ represents $C_{1-4}$alkyl optionally substituted with hydroxy; polyhalo$C_{1-4}$alkyl or $NR^6R^7$;

$R^9$ and $R^{10}$ each independently represent hydrogen; $C_{1-6}$alkyl; cyano; $C_{1-6}$alkylcarbonyl; $C_{1-4}$alkyloxy$C_{1-4}$alkyl; or $C_{1-4}$alkyl substituted with $C_{1-4}$alkyl-$NR^5$-;

$R^{11}$ represents $C_{1-4}$alkyl or $NR^9R^{10}$;

n1 represents an integer with value 1 or 2;

aryl represents phenyl or phenyl substituted with at least one substituent selected from halo, $C_{1-6}$alkyl, $C_{3-7}$cycloalkyl, $C_{1-6}$alkyloxy, cyano, nitro, polyhalo$C_{1-6}$alkyl or polyhalo$C_{1-6}$alkyloxy.

2. (Original) A compound according to claim 1 wherein

$R^2$ represents $C_{3-7}$cycloalkyl; phenyl or a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; or a radical of formula



(a-1)

wherein –B-C- represents a bivalent radical of formula

$-CH_2-CH_2-CH_2-$ (b-1);

$-CH_2-CH_2-CH_2-CH_2-$ (b-2);

$-X_3-CH_2-CH_2-(CH_2)_n-$ (b-3);

$-X_3-CH_2-(CH_2)_n-X_3-$ (b-4);

$-X_3-(CH_2)_{n'}-CH=CH-$ (b-5);

with $X_3$ representing O or $NR^5$;

n representing an integer with value 0, 1, 2 or 3;

n' representing an integer with value 0 or 1;

wherein said $R^2$ substituent, where possible, may optionally be substituted with at least one substituent selected from halo; hydroxy; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo$C_{1-6}$alkyl; $C_{1-6}$alkyloxy optionally substituted with carboxyl; polyhalo$C_{1-6}$alkyloxy; $C_{1-6}$alkylthio; polyhalo$C_{1-6}$alkylthio; $C_{1-6}$alkyloxycarbonyl; $C_{1-6}$alkylcarbonyloxy; $C_{1-6}$alkylcarbonyl; polyhalo$C_{1-6}$alkylcarbonyl; cyano; carboxyl; $NR^6R^7$; $C(=O)NR^6R^7$; $-NR^5-C(=O)-NR^6R^7$; $-NR^5-C(=O)-R^5$; $-S(=O)_{n1}-R^8$; $-NR^5-S(=O)_{n1}-R^8$; -S-CN; $-NR^5$-CN; or



with n2 representing an integer with value 0, 1, 2, 3 or 4;

with $X_4$ representing O, $NR^5$ or a direct bond;

with $X_5$ representing O or $NR^5$;

$X_2$ represents a direct bond; $-NR^1-$; -O-; -C(=O)-; -C(=S)-; -S-; $-S(=O)_{n1}-$; $-(CH_2)_{n3}-$; or $-(CH_2)_{n4}-X_{1a}-X_{1b}-$;

$R^3$ represents a 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, wherein said $R^3$ substituent, where possible, may optionally be substituted with at least one substituent selected from halo; hydroxy; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, $-C(=O)-NR^6R^7$, $-NR^5-C(=O)-NR^6R^7$, $-S(=O)_{n1}-R^8$ or $-NR^5-S(=O)_{n1}-R^8$; polyhalo$C_{1-6}$alkyl; $C_{1-6}$alkyloxy optionally substituted with carboxyl;

polyhalo$C_{1-6}$alkyloxy; $C_{1-6}$alkylthio; polyhalo$C_{1-6}$alkylthio; $C_{1-6}$alkyloxycarbonyl; $C_{1-6}$alkylcarbonyloxy; $C_{1-6}$alkylcarbonyl; polyhalo$C_{1-6}$alkylcarbonyl; cyano; carboxyl; $NR^6R^7$; $C(=O)NR^6R^7$; $-NR^5-C(=O)-NR^6R^7$; $-NR^5-C(=O)-R^5$; $-S(=O)_{n1}-R^8$; $-NR^5-S(=O)_{n1}-R^8$; -S-CN; $-NR^5-CN$; or  ; and in case $R^3$ represents a saturated 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, said $R^3$ may also be substituted with at least one oxo;

$R^5$ represents hydrogen or $C_{1-4}$alkyl;

$R^6$ and $R^7$ each independently represent hydrogen; cyano; $C_{1-6}$alkylcarbonyl; $C_{1-4}$alkyloxy$C_{1-4}$alkyl; $C_{1-4}$alkyl substituted with $C_{1-4}$alkyl-$NR^5$-; $C_{1-6}$alkyl optionally substituted with hydroxy, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $NR^{6a}R^{7a}$, $C(=O)NR^{6a}R^{7a}$ or  ;

$R^8$ represents $C_{1-4}$alkyl, polyhalo$C_{1-4}$alkyl or $NR^6R^7$.

3. (Previously presented) A compound as claimed in claim 1 wherein $R^1$ represents hydrogen or $C_{1-6}$alkyl; $X_1$ represents a direct bond or $-(CH_2)_{n3}-$; $R^2$ represents $C_{3-7}$cycloalkyl; phenyl; a 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl; or a radical of formula

 (a-1)

wherein –B-C- represents a bivalent radical of formula

$-CH_2-CH_2-CH_2-$ (b-1);

$-X_3-CH_2-(CH_2)_n-X_3-$ (b-4);

$-CH=N-X_3-$ (b-6);

with $X_3$ representing O or $NR^5$;

n representing an integer with value 1;

wherein said $R^2$ substituent, where possible, may optionally be substituted with at least one substituent, in particular with 1 or 2 substituents selected from halo; $C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $NR^6R^7$ or $-C(=O)-NR^6R^7$; polyhalo$C_{1-6}$alkyl; $C_{1-6}$alkyloxy optionally substituted with $C_{1-4}$alkyloxy; $C_{1-6}$alkylthio; $C_{1-6}$alkyl-

oxycarbonyl; cyano; arylthio; aryloxy; arylcarbonyl; $NR^6R^7$; $C(=O)NR^6R^7$; $-S(=O)_{n1}-R^8$; or imidazolyl optionally substituted with $C_{1-4}$alkyl; $X_2$ represents a direct bond; $-NR^1-$; $-O-(CH_2)_{n3}-$; $-C(=O)-$; $-C(=O)-NR^5-(CH_2)_{n3}-$; $-(CH_2)_{n3}-$; or $-S(=O)_{n1}-NR^5-(CH_2)_{n3}-NR^5-$; $R^3$ represents a 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, wherein said $R^3$ substituent, where possible, may optionally be substituted with at least one substituent selected from halo; hydroxy; $C_{1-6}$alkyl; or $NR^6R^7$; and in case $R^3$ represents a saturated or a partially saturated 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, said $R^3$ may also be substituted with at least one oxo; $R^4$ represents hydrogen; nitro or carboxyl; $R^5$ represents hydrogen; $R^6$ and $R^7$ each independently represent hydrogen; cyano; $C_{1-6}$alkylcarbonyl optionally substituted with $C_{1-4}$alkyloxy; $C_{1-6}$alkyloxycarbonyl; $C_{3-7}$cycloalkylcarbonyl; adamantanylcarbonyl; or $C_{1-6}$alkyl; $R^8$ represents $NR^6R^7$; n1 represents an integer with value 2; aryl represents phenyl.

4. (Previously presented) A compound as claimed in claim 1 wherein $R^1$ is hydrogen; $X_1$ is a direct bond or $-(CH_2)_{n3}-$; $R^2$ is indanyl; 2,3-dihydro-1,4-benzodioxanyl; phenyl optionally being substituted with 1 or 2 substituents each independently being selected from $C_{1-6}$alkyl which may optionally be substituted with hydroxy, cyano, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $NR^6R^7$ or $C(=O)NR^6R^7$; $C_{1-6}$alkyloxy; halo; polyhalo$C_{1-6}$alkyl which may optionally be substituted with hydroxy, cyano, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $NR^6R^7$ or $C(=O)NR^6R^7$; cyano; $NR^6R^7$; $C(=O)NR^6R^7$; $-S(=O)_{n1}-R^8$; $X_2$ is direct bond; $-NR^1-$; $-O-(CH_2)_{n3}-$; $-C(=O)-$; $-C(=O)-NR^5-(CH_2)_{n3}-$; or $-(CH_2)_{n3}-$; $R^3$ is tetrazolyl; piperazinyl; imidazolyl; oxazolyl; pyrimidinyl; thiazolyl; triazolyl; pyridyl; piperidinyl, pyrazinyl; pyrazolyl or morpholinyl; said rings representing $R^3$ may optionally be substituted with one substitutent selected from $C_{1-6}$alkyl; $NR^6R^7$; hydroxy; halo; and in case $R^3$ represents a saturated or a partially saturated ring system, said $R^3$ may also be substituted with at least one oxo; $R^4$ is hydrogen; $R^6$ and $R^7$ each independently represent hydrogen; cyano; $C_{1-6}$alkylcarbonyl optionally substituted with $C_{1-4}$alkyloxy; $C_{1-6}$alkyloxycarbonyl; $C_{3-7}$cycloalkylcarbonyl; or $C_{1-6}$alkyl; $R^8$ represents $NR^6R^7$.

5. (Previously presented) A compound as claimed in claim 1 wherein the $R^3$ substituent is linked to ring A in meta position compared to the $NR^1$ linker.

6. (Previously presented) A compound as claimed in claim 1 wherein the $R^3$ substituent is linked to ring A in para position compared to the $NR^1$ linker.

7. (Previously presented) A compound as claimed in claim 1 wherein the $R^3$ substituent is an optionally substituted saturated 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N.

8. (Previously presented) A compound as claimed in claim 1 wherein $X_1$ represents a direct bond.

9. (Previously presented) A compound as claimed in claim 1 wherein $R^2$ represents $C_{3-7}$cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula (a-1) wherein said $R^2$ substituent is substituted with at least one substituent selected from $C_{1-6}$alkyl substituted with $NR^6R^7$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each substituted with $NR^6R^7$; polyhalo$C_{1-6}$alkyl substituted with $NR^6R^7$; $C_{1-6}$alkyloxy substituted with $NR^6R^7$; polyhalo$C_{1-6}$alkyloxy substituted with $NR^6R^7$; or $NR^6R^7$.

10. (Previously presented) A compound as claimed in claim 1 wherein $R^3$ represents a 5-or 6-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N, or a 9-or 10-membered bicyclic heterocycle containing at least one heteroatom selected from O, S or N, wherein said $R^3$ substituent is substituted with at least one substituent selected from $C_{1-6}$alkyl substituted with $NR^6R^7$; $C_{2-6}$alkenyl or $C_{2-6}$alkynyl, each substituted with $NR^6R^7$; $C_{1-6}$alkyloxy substituted with $NR^6R^7$; or $NR^6R^7$.

11. (Previously presented) A compound as claimed in claim 1 wherein $R^2$ represents $C_{3-7}$cycloalkyl; phenyl; a 4, 5, 6- or 7-membered monocyclic heterocycle containing at least one heteroatom selected from O, S or N; benzoxazolyl or a radical of formula (a-1), wherein said $R^2$ substituent is substituted with at least one substituent selected from halo; polyhalo$C_{1-6}$alkyl optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy-$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, -C(=O)-$NR^6R^7$, -$NR^5$-C(=O)-$NR^6R^7$, -$S(=O)_{n1}$-$R^8$ or –$NR^5$-$S(=O)_{n1}$-$R^8$; polyhalo-$C_{1-6}$alkyloxy optionally substituted with at least one substituent selected from hydroxy, cyano, carboxyl, $C_{1-4}$alkyloxy, $C_{1-4}$alkyloxy$C_{1-4}$alkyloxy, $C_{1-4}$alkylcarbonyl, $C_{1-4}$alkyloxycarbonyl, $C_{1-4}$alkylcarbonyloxy, $NR^6R^7$, -C(=O)-$NR^6R^7$, -$NR^5$-C(=O)-$NR^6R^7$, -$S(=O)_{n1}$-$R^8$ or –$NR^5$-$S(=O)_{n1}$-$R^8$.

12. (Previously Presented) A compound as claimed in claim 1 wherein the compound is selected from



| $X_1$ | $R^2$ | $X_2$ | $R^3$ |
|---|---|---|---|
| db |  | 2-db |  |
| db |  | 2-db |  |
| db |  | 2-db |  |
| db |  | 2-db |  |
| db |  | 2-db |  |
| db |  | 3-db |  |
| db |  | 2-db |  |
| db |  | 3-NH |  |
| db |  | 2-db |  |

| $X_1$ | $R^2$ | $X_2$ | $R^3$ |
|---|---|---|---|
| db |  | 3-db |  |

a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.

13. (Previously Presented) A compound as claimed in claim 1 wherein the compound is selected from



| $X_1$ | $R^2$ | $-X_2-R^3$ |
|---|---|---|
| db |  |  |
| db |  |  |
| db |  |  |
| db |  |  |
| db |  |  |
| db |  |  |
| db |  |  |

a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof.

14. (Previously presented) A pharmaceutical composition comprising a compound as claimed in claim 1 and a pharmaceutical excipient.

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient ~~a therapeutically effective amount of~~ a compound as claimed in claim 1.

19. (Previously presented) A process for preparing a pharmaceutical composition comprising mixing a compound as claimed in claim 1 with a pharmaceutically acceptable carrier.

20. (Previously Presented) A process for preparing a compound as claimed in claim 1, comprising

a) cyclizing an intermediate of formula (II) in the presence of a nitrite salt, a suitable solvent, and a suitable acid,




(II) (I)

wherein ring A, $R^1$ to $R^4$, $X_1$ and $X_2$ are as defined in claim 1;

b) cyclizing an intermediate of formula (II-a) in the presence of a nitrite salt, a suitable solvent, and a suitable acid,




(II-a) (I-a) (I-b)

wherein ring A, $R^1$ to $R^3$, $X_1$ and $X_2$ are as defined in claim 1;

c) cyclizing an intermediate of formula (II-b) in the presence of a nitrite salt, a suitable solvent, and a suitable acid,




(II-b) (I-c)

wherein ring A, $R^1$, $R^3$ and $R^4$, $X_1$ and $X_2$ are as defined in claim 1;

d) reacting an intermediate of formula (III) with an intermediate of formula (IV) in the presence of a suitable solvent,



(III) (IV) (I)

wherein ring A, $R^1$ to $R^4$, $X_1$ and $X_2$ are as defined in claim 1;

e) reacting an intermediate of formula (XV) with an intermediate of formula (XVI), wherein $R^b$ represents hydrogen, $C_{1-4}$alkyl or cyano, and $R^c$ represents hydrogen or $C_{1-4}$alkyl, in the presence of a suitable solvent and a suitable salt



(XV) (XVI) (I-d)

wherein ring A, $R^1$ $R^2$, $R^4$ and $X_1$ are as defined in claim 1;

f) reacting an intermediate of formula (XV) with hydrazine in the presence of a suitable solvent,



(XV) (I-e)

wherein ring A, $R^1$ $R^2$, $R^4$ and $X_1$ are as defined in claim 1;

g) reacting an intermediate of formula (III') with an intermediate of formula (IV) in the presence of a suitable solvent, and optionally in the presence of a suitable base,



(III') (IV) (I)

wherein ring A, $R^1$ $R^2$, $R^3$, $R^4$, $X_1$ and $X_2$ are as defined in claim 1;

and optionally converting compounds of formula (I) into each other following art-known transformations, and further, optionally converting the compounds of formula (I), into a

therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, optionally preparing stereochemically isomeric forms or quaternary amines thereof.